MATTHEW BOYTE: Open Payments
NPI 1366949133 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,647 in 82 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $43 · 2025 $1,647
Food & beverage: $1,647
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $281 |
| Alkermes, Inc. | 11 | $274 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $263 |
| Vanda Pharmaceuticals Inc. | 7 | $156 |
| Otsuka America Pharmaceutical, Inc. | 7 | $139 |
| E.R. Squibb & Sons, L.L.C. | 6 | $115 |
| Corium, LLC | 6 | $99 |
| Alpha Cognition USA, Inc. | 1 | $92 |
| Neurocrine BioSciences, Inc. | 2 | $60 |
| Lundbeck LLC | 3 | $57 |
Products named: VRAYLAR, ARISTADA, CAPLYTA, FANAPT, REXULTI, COBENFY, Azstarys, Zunveyl.
Industry payments across AL — which companies pay providers there.
